Trials / Terminated
TerminatedNCT01812213
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Navidea Biopharmaceuticals · Industry
- Sex
- All
- Age
- 55 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
To investigate whether \[18F\]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]NAV4694 |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2017-11-02
- Completion
- 2017-11-02
- First posted
- 2013-03-18
- Last updated
- 2024-08-14
- Results posted
- 2024-08-14
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01812213. Inclusion in this directory is not an endorsement.